NCT02113436View on ClinicalTrials.gov

Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial Asthma

PHASE4CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

May 1, 2014

Primary Completion Date

June 1, 2016

Study Completion Date

October 1, 2016

Conditions
Asthma
Interventions
DRUG

FP/ SLM HFA MDI 50/25 mcg

Metered-dose aerosol product containing 50 mcg of fluticasone propionate and 25 mcg of salmeterol per inhalation

DRUG

FP HFA MDI 50 mcg

Metered-dose aerosol product containing 50 mcg of fluticasone propionate per inhalation

Trial Locations (69)

451-0052

GSK Investigational Site, Aichi

470-1192

GSK Investigational Site, Aichi

260-0001

GSK Investigational Site, Chiba

273-0032

GSK Investigational Site, Chiba

284-0003

GSK Investigational Site, Chiba

790-8524

GSK Investigational Site, Ehime

910-0833

GSK Investigational Site, Fukui

910-8526

GSK Investigational Site, Fukui

918-8205

GSK Investigational Site, Fukui

802-8533

GSK Investigational Site, Fukuoka

811-1394

GSK Investigational Site, Fukuoka

811-3195

GSK Investigational Site, Fukuoka

813-0017

GSK Investigational Site, Fukuoka

814-0123

GSK Investigational Site, Fukuoka

500-8717

GSK Investigational Site, Gifu

370-0841

GSK Investigational Site, Gunma

372-0817

GSK Investigational Site, Gunma

720-8520

GSK Investigational Site, Hiroshima

730-0844

GSK Investigational Site, Hiroshima

730-8518

GSK Investigational Site, Hiroshima

734-0023

GSK Investigational Site, Hiroshima

737-0023

GSK Investigational Site, Hiroshima

738-8503

GSK Investigational Site, Hiroshima

006-0831

GSK Investigational Site, Hokkaido

064-0821

GSK Investigational Site, Hokkaido

069-0816

GSK Investigational Site, Hokkaido

070-0832

GSK Investigational Site, Hokkaido

070-8530

GSK Investigational Site, Hokkaido

078-8211

GSK Investigational Site, Hokkaido

078-8811

GSK Investigational Site, Hokkaido

650-0047

GSK Investigational Site, Hyōgo

653-0021

GSK Investigational Site, Hyōgo

674-0068

GSK Investigational Site, Hyōgo

300-0028

GSK Investigational Site, Ibaraki

302-0022

GSK Investigational Site, Ibaraki

312-0057

GSK Investigational Site, Ibaraki

920-8616

GSK Investigational Site, Ishikawa

765-0033

GSK Investigational Site, Kagawa

216-0006

GSK Investigational Site, Kanagawa

221-0014

GSK Investigational Site, Kanagawa

222-0012

GSK Investigational Site, Kanagawa

224-0001

GSK Investigational Site, Kanagawa

231-8682

GSK Investigational Site, Kanagawa

238-8567

GSK Investigational Site, Kanagawa

250-8558

GSK Investigational Site, Kanagawa

861-8520

GSK Investigational Site, Kumamoto

514-0125

GSK Investigational Site, Mie

983-0816

GSK Investigational Site, Miyagi

700-8607

GSK Investigational Site, Okayama

556-0005

GSK Investigational Site, Osaka

565-0862

GSK Investigational Site, Osaka

583-8588

GSK Investigational Site, Osaka

840-8571

GSK Investigational Site, Saga

344-0011

GSK Investigational Site, Saitama

351-0102

GSK Investigational Site, Saitama

360-0018

GSK Investigational Site, Saitama

360-0812

GSK Investigational Site, Saitama

321-0293

GSK Investigational Site, Tochigi

152-0021

GSK Investigational Site, Tokyo

154-0002

GSK Investigational Site, Tokyo

154-0017

GSK Investigational Site, Tokyo

157-0066

GSK Investigational Site, Tokyo

158-0094

GSK Investigational Site, Tokyo

173-0015

GSK Investigational Site, Tokyo

176-0012

GSK Investigational Site, Tokyo

190-0023

GSK Investigational Site, Tokyo

196-0003

GSK Investigational Site, Tokyo

202-0004

GSK Investigational Site, Tokyo

646-8558

GSK Investigational Site, Wakayama

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02113436 - Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial Asthma | Biotech Hunter | Biotech Hunter